Skip to content
The Nexus
DossierENTITY

cell and gene therapies

Coverage of cell and gene therapies in the Nexus archive.

Earliest in view: Jul 2 · 18:04 UTCMost recent: Jul 25 · 11:30 UTC
Co-mentioned in this coverage
daraxonrasibtopic1Revolution Medicineorganization1Innovation Treadmilltopic1Lipitortopic1Pfizerorganization1Human Genome Projecttopic1FDAorganization1Centreorganization1Drugs Rules, 1945topic1stem cell-derived productstopic1regenerative treatmentstopic1CAR-T cell therapiestopic1blood cancerstopic1leukemiastopic1lymphomastopic1
Recent coverage
  • HEALTHJul 25 · 11:30 UTCFORTUNE
    When 10,000 doctors stood up and cheered for a cancer drug — America’s innovation machine made it possible

    A cancer drug, daraxonrasib, developed by Revolution Medicine, nearly doubled survival rates for pancreatic cancer, sparking a standing ovation at a conference. The article highlights the U.S. innovation model, the 'Innovation Treadmill,' which balances high drug prices with rapid generic substitution to sustain medical breakthroughs. It contrasts U.S. drug access with European delays and discusses trends like genetic advancements and AI in biotech.

  • HEALTHJul 2 · 18:04 UTCTHE HINDU NATIONAL
    Centre amends Drugs Rules, 1945 to ensure uniform regulation of advance cell and gene therapies

    The Centre has amended the Drugs Rules, 1945 to establish uniform regulation for advanced cell and gene therapies, including stem cell-based regenerative treatments and CAR-T cell therapies. These therapies are increasingly used to treat blood cancers like leukemias and lymphomas, and the amendment aims to strengthen regulatory oversight of emerging medical technologies.